摘要
BackgroundEnzalutamide, as a second-generation endocrine therapy drug for prostate cancer (PCa), is prominent representative among the synthetic androgen receptor antagonists. Currently, there is lack of enzalutamide-induced signature (ENZ-sig) for predicting progression and relapse-free survival (RFS) in PCa. MethodsEnzalutamide-induced candidate markers were derived from single-cell RNA sequencing analysis integrating three enzalutamide-stimulated models (0-, 48-, and 168-h enzalutamide stimulation). ENZ-sig was constructed on the basis of candidate genes that were associated with RFS in The Cancer Genome Atlas leveraging least absolute shrinkage and selection operator method. The ENZ-sig was further validated in GSE70768, GSE94767, E-MTAB-6128, DFKZ, GSE21034, and GSE70769 datasets. Biological enrichment analysis was used to discover the underlying mechanism between high ENZ-sig and low ENZ-sig in single-cell RNA sequencing and bulk RNA sequencing. ResultsWe identified a heterogenous subgroup that induced by enzalutamide stimulation and found 53 enzalutamide-induced candidate markers that are related to trajectory progression and enzalutamide-stimulated. The candidate genes were further narrowed down into 10 genes that are related to RFS in PCa. A 10-gene prognostic model (ENZ-sig)-IFRD1, COL5A2, TUBA1A, CFAP69, TMEM388, ACPP, MANEA, FOSB, SH3BGRL, and ST7-was constructed for the prediction of RFS in PCa. The effective and robust predictability of ENZ-sig was verified in six independent datasets. Biological enrichment analysis revealed that differentially expressed genes in high ENZ-sig were more activated in cell cycle-related pathway. High-ENZ-sig patients were more sensitive to cell cycle-targeted drugs (MK-1775, AZD7762, and MK-8776) than low-ENZ-sig patients in PCa. ConclusionsOur results provided evidence and insight on the potential utility of ENZ-sig in PCa prognosis and combination therapy strategy of enzalutamide and cell cycle-targeted compounds in treating PCa.
学科与关键词
- Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancerMarcus Moses; Alex Niu; Michael B. Lilly; Andrew W Hahn; Roberto Nussenzveig; Elisa Ledet; Charlotte Manogue; Patrick Cotogno; Brian Lewis; Jodi Layton; Neeraj Agarwal; Oliver Sartor; Pedro C. BarataCancer Treatment and Research Communications, 2020, 100193.
- IU1 and enzalutamide combination yields synergistic effects on castration-resistant prostate cancerZhang, Yifan; Liao, Yuanpeng; Luo, Mayao; Ye, Yuedian; Xu, Zhuofan; Hou, Wenli; Liu, Ruiyu; Zhai, Qiliang; Lv, Shidong*; Wei, Qiang*PROSTATE, 2023, 83(15): 1446-1457.
- Inflammation-related signature for prognostic prediction, tumor immune, genomic heterogeneity, and drug choices in prostate cancer: Integrated analysis of bulk and single-cell RNA-sequencingZhu, Weian; Huang, Jiongduan; Wu, Jianjie; Wu, Chenglun; Ye, Fengxi; Li, Xiang*; Lai, Wenjie*Heliyon, 2023, 9(11): e21174.
